Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Pharmacogenet Genomics. 2013 Mar;23(3):135–141. doi: 10.1097/FPC.0b013e32835d9ab0

Table 2.

Pharmacokinetic Parameters for Bupropion and Metabolites (mean, 95% CI)

All (N=42) No reduced function allele (N=16) With reduced function allele(s) (N=26) *6 allele (N= 23) *18 allele (N= 2) *6/18 allele (N= 1)
BUP
 Cmax (ng/mL) 58 (52,63) 58 (51,65) 57 (48, 66) 58 (50,67) 59 (-2,121) 33

  Css (ng/mL) 28.5 (26.3,30.8) 29.4 (26.6,32.1) 28.0 (24.7,31.4) 28.6 (25.6,31.7) 25.9 (25.6,226.5) 18.8

 AUC (hr•ng/mL) 685 (631,739) 705 (639,770) 673 (593, 753) 687 (614,761) 621 (-614,5437) 450

HB
 Cmax (ng/mL) 464 (406,522) 592 (493,690) 386a (330, 442) 405a (352,459) 291 (130,452) 137

  Css (ng/mL) 397 (347,447) 501 (410,591) 333b (285,381) 349b (301,397) 258 (-992,1509) 115

 AUC (hr•ng/mL) 9524 (8319,10729) 12015 (9852,14177) 7996a (6833,9149) 8375b (7219,9531) 6200 (-23812,36212) 2753

HB/BUP 14.4 (12.6,16.2) 17.4 (14.1,20.8) 12.5c (10.6, 14.4) 12.8c (10.8,14.8) 12.2 (-34.2,58.6) 6.1

EB
 Cmax (ng/mL) 38 (35,42) 43 (37,49) 35 (31,41) 36 (31,41) 38 (-1,77) 22

  Css (ng/mL) 32 (29,36) 36 (30,42) 30 (25,34) 30 (26,34) 31 (-183,246) 19

 AUC (hr·ng/mL) 772 (689,856) 868 (727,1008) 713 (609,817) 721 (618,825) 753 (-4393,5899) 444

 EB/BUP 1.15 (1.05,1.25) 1.24 (1.07,1.42) 1.09 (0.96,1.22) 1.08 (0.93,1.23) 1.30 (-0.48,3.08) 0.99

TB
 Cmax (ng/mL) 208 (181,236) 241 (190,293) 188 (157, 218) 188 (159,216) 222 (-9,453) 122

  Css (ng/mL) 175 (150,200) 204 (153,255) 158 (132,182) 157 (132,182) 190 (-1220,1599) 108

 AUC (hr•ng/mL) 4209 (3612,4807) 4893 (3661,6126) 3789 (3170, 4407) 3775 (3178,4371) 4549 (-29275,38373) 2582

 TB/BUP 6.21 (5.53,6.90) 6.93 (5.53,8.32) 5.77 (5.04, 6.50) 5.62 (4.82,6.42) 7.50 (3.78,11.23) 5.73

Significant differences compared to no reduced function allele group

a

P = 0.005

b

P < 0.001

c

P = 0.01